Table 3 Therapeutic intervention of patients with SJIA
Treatment | ILD (n = 35) | Non-ILD (n = 141) | P value |
|---|---|---|---|
Methotrexate | 25 (71.4) | 113 (80.1) | 0.262 |
Sulfasalazine | 2 (5.7) | 11 (7.8) | 0.951 |
Leflunomide | 10 (28.6) | 16 (11.3) | 0.010* |
Thalidomide | 10 (28.6) | 28 (19.9) | 0.262 |
Hydroxychloroquine | 5 (14.3) | 2 (1.4) | 0.003** |
Cyclosporine | 12 (34.3) | 27 (19.1) | 0.054 |
Tacrolimus | 1 (2.9) | 1 (0.7) | 0.359 |
Cyclophosphamide | 3 (8.6) | 0 (0.0) | 0.007** |
bDMARDs | 19 (54.3) | 78 (55.3) | 0.912 |
 Etanercept | 2 (5.7) | 12 (8.5) | 0.843 |
 Infliximab | 2 (5.7) | 5 (3.5) | 0.917 |
 Adalimumab | 2 (5.7) | 6 (4.3) | 1.000 |
 Tocilizumab | 18 (51.4) | 73 (51.8) | 0.971 |
Combination therapy# | 19 (54.3) | 42 (29.8) | 0.006** |
IVIG | 20 (57.1) | 63 (44.7) | 0.186 |
High-dose corticosteroids## | 32 (91.4) | 102 (72.3) | 0.018* |
Pulse therapy | 8 (22.9) | 29 (20.6) | 0.766 |